Reduction ofmyeloid-derived suppressor cells in prostate cancer murinemodels and patients following white button mushroom treatment

Abstract

	•White button mushroom (WBM) treatment resulted in a reduction in pro-tumoural MDSCs, notably polymorphonuclear MDSCs (PMN-MDSCs), along with activation of anti-tumoural T and NK cells.
	•Human single immune cell gene expression profiling shed light on the molecular alterations induced by WBM, specifically on PMN-MDSCs.
	•A proof-of-concept study combining WBM with PD-1 blockade in murine models revealed an additive effect on tumour regression and survival outcomes, highlighting the clinical relevance of WBM in cancer management.

Keywords

clinical trial / myeloid-derived suppressor cells (MDSCs) / nutraceutical intervention / prostate cancer / single immune cell profiling / white button mushroom

References

[1] VegliaF, Sanseviero E, GabrilovichDI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. 2021; 21: 485-498.

[2] KoinisF, XagaraA, ChantzaraE, Leontopoulou V, AidarinisC, KotsakisA. Myeloid-derived suppressor cells in prostate cancer: present knowledge and future perspectives. Cells. 2021; 11(1): 20.

[3] MonuNR, FreyAB. Myeloid-derived suppressor cells and anti-tumor T cells: a complex relationship. Immunol Invest. 2012; 41(6-7): 595-613.

[4] BrunoA, Mortara L, BaciD, NoonanDM, AlbiniA. Myeloid derived suppressor cells interactions with natural killer cells and pro-angiogenic activities: roles in tumor progression. Front Immunol. 2019; 10: 771.

[5] WuY, YiM, NiuM, MeiQ, WuK. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy. Mol Cancer. 2022; 21(1): 184.

[6] LiK, ShiH, ZhangB, et al. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduct Target Ther. 2021; 6(1): 362.

[7] ReedD, RainaK, AgarwalR. Nutraceuticals in prostate cancer therapeutic strategies and their neo-adjuvant use in diverse populations. NPJ Precis Oncol. 2018; 2: 15.

[8] Food as medicine: translating the evidence. Nat Med. 2023; 29(4): 753-754.

[9] MoranAJ, Roberto CA. A “food is medicine” approach to disease prevention: limitations and alternatives. JAMA. 2023; 330(23): 2243-2244.

[10] ParkHJ. Current uses of mushrooms in cancer treatment and their anticancer mechanisms. Int J Mol Sci. 2022; 23(18): 10502.

[11] JeitlerM, Michalsen A, FringsD, et al. Significance of medicinal mushrooms in integrative oncology: a narrative review. Front Pharmacol. 2020; 11: 580656.

[12] SiwulskiM, BudkaA, RzymskiP, et al. Worldwide basket survey of multielemental composition of white button mushroom Agaricus bisporus. Chemosphere. 2020; 239: 124718.

[13] BlumfieldM, AbbottK, DuveE, Cassettari T, MarshallS, Fayet-MooreF. Examining the health effects and bioactive components in Agaricus bisporus mushrooms: a scoping review. J Nutr Biochem. 2020; 84: 108453.

[14] AdamsLS, PhungS, WuX, KiL, ChenS. White button mushroom (Agaricus bisporus) exhibits antiproliferative and proapoptotic properties and inhibits prostate tumor growth in athymic mice. Nutr Cancer. 2008; 60(6): 744-756.

[15] WangX, HaD, MoriH, Chen S. White button mushroom (Agaricus bisporus) disrupts androgen receptor signaling in human prostate cancer cells and patient-derived xenograft. J Nutr Biochem. 2021; 89: 108580.

[16] WangX, HaD, YoshitakeR, Chen S. White button mushroom interrupts tissue AR-mediated TMPRSS2 expression and attenuates pro-inflammatory cytokines in C57BL/6 mice. NPJ Sci Food. 2021; 5(1): 20.

[17] TwardowskiP, KanayaN, FrankelP, et al. A phase I trial of mushroom powder in patients with biochemically recurrent prostate cancer: roles of cytokines and myeloid-derived suppressor cells for Agaricus bisporus-induced prostate-specific antigen responses. Cancer. 2015; 121(17): 2942-2950.

[18] KimJ, Coetzee GA. Prostate specific antigen gene regulation by androgen receptor. J Cell Biochem. 2004; 93(2): 233-241.

[19] TimmTG, CostaTM, AlbertonMD, Helm CV, TavaresLBB. Mushroom β-glucans: application and innovation for food industry and immunotherapy. Appl Microbiol Biotechnol. 2023; 107(16): 5035-5049.

[20] AlbeituniSH, DingC, LiuM, et al. Yeast-derived particulate β-glucan treatment subverts the suppression of myeloid-derived suppressor cells (MDSC) by inducing polymorphonuclear MDSC apoptosis and monocytic MDSC differentiation to APC in cancer. J Immunol. 2016; 196(5): 2167-2180.

[21] ChanputW, MesJJ, WichersHJ. THP-1 cell line: an in vitro cell model for immune modulation approach. Int Immunopharmacol. 2014; 23(1): 37-45.

[22] ChanputW, Reitsma M, KleinjansL, MesJJ, Savelkoul HF, WichersHJ. β-Glucans are involved in immune-modulation of THP-1 macrophages. Mol Nutr Food Res. 2012; 56(5): 822-833.

[23] FengS, ChengX, ZhangL, et al. Myeloid-derived suppressor cells inhibit T cell activation through nitrating LCK in mouse cancers. Proc Natl Acad Sci U S A. 2018; 115(40): 10094-10099.

[24] NohMG, KimSS, KimYJ, et al. Evolution of the tumor microenvironment toward immune-suppressive seclusion during brain metastasis of breast cancer: implications for targeted therapy. Cancers (Basel). 2021; 13(19): 4895.

[25] JiangZ, SunH, YuJ, TianW, SongY. Targeting CD47 for cancer immunotherapy. J Hematol Oncol. 2021; 14(1): 180.

[26] AlsaabHO, SauS, AlzhraniR, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017; 8: 561.

[27] GroomJR, LusterAD. CXCR3 in T cell function. Exp Cell Res. 2011; 317(5): 620-631.

[28] MascarelliDE, RosaRSM, ToscaroJM, et al. Boosting antitumor response by costimulatory strategies driven to 4-1BB and OX40 T cell receptors. Front Cell Dev Biol. 2021; 9: 692982.

[29] BedsaulJR, CarterNM, DeibelKE, et al. Mechanisms of regulated and dysregulated CARD11 signaling in adaptive immunity and disease. Front Immunol. 2018; 9: 2105.

[30] DanaherP, WarrenS, DennisL, et al. Gene expression markers of tumor infiltrating leukocytes. J Immunother Cancer. 2017; 5: 18.

[31] GaikwadS, Agrawal MY, KaushikI, RamachandranS, Srivastava SK. Immune checkpoint proteins: signaling mechanisms and molecular interactions in cancer immunotherapy. Semin Cancer Biol. 2022; 86(3): 137-150.

[32] BronteV, Brandau S, ChenSH, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016; 7: 12150.

[33] AlshetaiwiH, Pervolarakis N, McIntyreLL, et al. Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics. Sci Immunol. 2020; 5(44): eaay6017.

[34] RieberN, SinghA, ÖzH, et al. Pathogenic fungi regulate immunity by inducing neutrophilic myeloid-derived suppressor cells. Cell Host Microbe. 2015; 17(4): 507-514.

[35] LiY, HeH, JihuR, Zhou J, ZengR, YanH. Novel characterization of myeloid-derived suppressor cells in tumor microenvironment. Front Cell Dev Biol. 2021; 9: 698532.

[36] CondamineT, MastioJ, GabrilovichDI. Transcriptional regulation of myeloid-derived suppressor cells. J Leukoc Biol. 2015; 98(6): 913-922.

[37] HegdeS, LeaderAM, MeradM. MDSC: markers, development, states, and unaddressed complexity. Immunity. 2021; 54(5): 875-884.

[38] DuarteD, ValeN. Evaluation of synergism in drug combinations and reference models for future orientations in oncology. Curr Res Pharmacol Drug Discov. 2022; 3: 100110.

[39] RyallKA, TanAC. Systems biology approaches for advancing the discovery of effective drug combinations. J Cheminform. 2015; 7: 7.

[40] LiD, XuW, ChangY, Xiao Y, HeY, RenS. Advances in landscape and related therapeutic targets of the prostate tumor microenvironment. Acta Biochim Biophys Sin (Shanghai). 2023; 55(6): 956-973.

[41] WangY, JiaA, BiY, et al. Targeting myeloid-derived suppressor cells in cancer immunotherapy. Cancers. 2020; 12(9): 2626.

[42] VegliaF, Hashimoto A, DweepH, et al. Analysis of classical neutrophils and polymorphonuclear myeloid-derived suppressor cells in cancer patients and tumor-bearing mice. J Exp Med. 2021; 218(4): e20201803.

[43] Lopez-BujandaZ, DrakeCG. Myeloid-derived cells in prostate cancer progression: phenotype and prospective therapies. J Leukoc Biol. 2017; 102(2): 393-406.

[44] HaoZ, LiR, WangY, Li S, HongZ, HanZ. Landscape of myeloid-derived suppressor cell in tumor immunotherapy [published correction appears in Biomark Res. 2022 Feb 7;10(1):7]. Biomark Res. 2021; 9(1): 77.

[45] KohadaY, Kuromoto A, TakedaK, et al. Circulating PMN-MDSC level positively correlates with a poor prognosis in patients with metastatic hormone-sensitive prostate cancer. FrontUrol. 2022; 2: 967480.

[46] FlemingV, HuX, WeberR, et al. Targeting myeloid-derived suppressor cells to bypass tumor-induced immunosuppression. Front Immunol. 2018; 9: 398.

[47] VetterJ. The mushroom glucans: molecules of high biological and medicinal importance. Foods. 2023; 12(5): 1009.

[48] ChanGC, ChanWK, SzeDM. The effects of beta-glucan on human immune and cancer cells. J Hematol Oncol. 2009; 2: 25.

[49] LiX, RuanQ, YangW, et al. Polysaccharide isolated from Grifola frondosa eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T cells responses. Int J Biol Sci. 2024; 20(2): 664-679.

[50] MasudaY, Nakayama Y, ShimizuR, et al. Maitake α-glucan promotes differentiation of monocytic myeloid-derived suppressor cells into M1 macrophages. Life Sci. 2023; 317: 121453.

[51] MasudaY, InoueH, OhtaH, Miyake A, KonishiM, NanbaH. Oral administration of soluble β-glucans extracted from Grifola frondosa induces systemic antitumor immune response and decreases immunosuppression in tumor-bearing mice. Int J Cancer. 2013; 133(1): 108-119.

[52] WuH, TaoN, LiuX, et al. Polysaccharide from Lentinus edodes inhibits the immunosuppressive function of myeloid-derived suppressor cells. PLoS One. 2012; 7(12): e51751.

[53] RenZ, GuoZ, MeydaniSN, Wu D. White button mushroom enhances maturation of bone marrow-derived dendritic cells and their antigen presenting function in mice. J Nutr. 2008; 138(3): 544-550.

[54] WuD, PaeM, RenZ, GuoZ, SmithD, Meydani SN. Dietary supplementation with white button mushroom enhances natural killer cell activity in C57BL/6 mice. J Nutr. 2007; 137(6): 1472-1477.

[55] CaseS, O’Brien T, LedwithAE, et al. β-glucans from Agaricus bisporus mushroom products drive trained immunity. Front Nutr. 2024; 11: 1346706.

[56] LiuY, ZhengD, WangD, Su L, WangQ, LiY. Immunomodulatory activities of polysaccharides from white button mushroom, Agaricus bisporus (Agaricomycetes), fruiting bodies and cultured mycelia in healthy and immunosuppressed mice. Int J Med Mushrooms. 2019; 21(1): 13-27.

[57] CerlettiC, Esposito S, IacovielloL. Edible mushrooms and beta-glucans: impact on human health. Nutrients. 2021; 13(7): 2195.

[58] SariM, PrangeA, LelleyJI, Hambitzer R. Screening of beta-glucan contents in commercially cultivated and wild growing mushrooms. Food Chem. 2017; 216: 45-51.

[59] BlumfieldM, AbbottK, DuveE, Cassettari T, MarshallS, Fayet-MooreF. Examining the health effects and bioactive components in Agaricus bisporus mushrooms: a scoping review. J Nutr Biochem. 2020; 84: 108453.

[60] WangX, ChanYS, WongK, et al. Mechanism-driven and clinically focused development of botanical foods as multitarget anticancer medicine: collective perspectives and insights from preclinical studies, IND applications and early-phase clinical trials. Cancers (Basel). 2023; 15(3): 701.

[61] ShipkowskiKA, BetzJM, BirnbaumLS, et al. Naturally complex: perspectives and challenges associated with Botanical Dietary Supplement Safety assessment. Food Chem Toxicol. 2018; 118: 963-971.

[62] Botanical Drug Development Guidance for Industry. Docket Number: FDA-2000-D-0103. Issued by: Center for Drug Evaluation and Research. 2016. Accessed on 13 January 2023. Available online: https://www.FDA.gov/regulatory-information/search-FDA-guidance-documents/botanical-drug-development-guidance-industry

[63] SorkinBC, KuszakAJ, BlossG, et al. Improving natural product research translation: from source to clinical trial. FASEB J. 2019; 34: 41-65.

[64] OlsonB, LiY, LinY, LiuET, PatnaikA. Mouse models for cancer immunotherapy research. Cancer Discov. 2018; 8(11): 1358-1365.

[65] GrabowskaMM, DeGraff DJ, YuX, et al. Mouse models of prostate cancer: picking the best model for the question. Cancer Metastasis Rev. 2014; 33(2-3): 377-397.

[66] Jimenez VeraE, ChewYV, NicholsonL, et al. Standardisation of flow cytometry for whole blood immunophenotyping of islet transplant and transplant clinical trial recipients. PLoS One. 2019; 14(5): e0217163.

[67] Isolation of leukocytes, bone marrow and peripheral blood mononuclear cells for single cell RNA sequencing. Accessed on 9 August 2024. Available online: https://www.10xgenomics.com/support/single-cell-gene-expression/documentation/steps/sample-prep/isolation-of-leukocytes-bone-marrow-and-peripheral-blood-mononuclear-cells-for-single-cell-rna-sequencing

[68] Capturing neutrophils in 10x single cell gene expression data. Accessed on 9 August 2024. Available online: https://www.10xgenomics.com/support/software/cell-ranger/latest/tutorials/cr-tutorial-neutrophils

[69] HaoY, HaoS, Andersen-NissenE, et al. Integrated analysis of multimodal single-cell data. Cell. 2021; 184(13): 3573-3587.

[70] XieX, ShiQ, WuP, et al. Single-cell transcriptome profiling reveals neutrophil heterogeneity in homeostasis and infection. Nat Immunol. 2020; 21(9): 1119-1133.

[71] WuT, HuE, XuS, et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation (Camb). 2021; 2(3): 100141.

[72] PhilippouY, Sjoberg HT, MurphyE, et al. Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model. Br J Cancer. 2020; 123(7): 1089-1100.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.